PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15164328-6	2004	Candesartan treatment resulted in a significant decrease of systolic and diastolic blood pressures, LV mass index (LVMI), homeostasis model assessment (HOMA) index, and plasma brain natriuretic peptide (BNP).	candesartan	0-11	natriuretic peptide B	Homo sapiens	176-201	
22406464-5	2012	When we divided participants by their time of candesartan administration, the relationship between the decrease in log-transformed BNP and asleep SBP was still significant in both the awakening-dosing group (beta = 0.21, P = 0.028) and the bedtime-dosing group (beta = 0.21, P = 0.029).	candesartan	46-57	natriuretic peptide B	Homo sapiens	131-134	
22406464-7	2012	CONCLUSION: The decrease in BNP is associated with asleep BP reduction by candesartan (+ diuretics as needed) over and above the awake BP reduction, regardless of the time of administration.	candesartan	74-85	natriuretic peptide B	Homo sapiens	28-31	
22302146-2	2012	In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of candesartan in patients with HF and preserved (LVEF >= 40%) or depressed (LVEF <40%) LV systolic function.	candesartan	171-182	natriuretic peptide B	Homo sapiens	136-161	
22302146-2	2012	In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of candesartan in patients with HF and preserved (LVEF >= 40%) or depressed (LVEF <40%) LV systolic function.	candesartan	171-182	natriuretic peptide B	Homo sapiens	163-166	
19294444-6	2009	Candesartan produced early and sustained improvements of plasma BNP/NT-pro-BNP, LVEF, and quality of life (SF-36) compared to baseline.	candesartan	0-11	natriuretic peptide B	Homo sapiens	64-67	
19294444-6	2009	Candesartan produced early and sustained improvements of plasma BNP/NT-pro-BNP, LVEF, and quality of life (SF-36) compared to baseline.	candesartan	0-11	natriuretic peptide B	Homo sapiens	75-78	
15734608-11	2005	There was a significant correlation between the changes in (123)I-MIBG scintigraphic findings and the percent change in BNP from baseline to six months in patients receiving candesartan (TDS: r = 0.587, p < 0.005; H/M ratio: r = -0.509, p < 0.01; WR: r = 0.602, p < 0.005).	candesartan	174-185	natriuretic peptide B	Homo sapiens	120-123	
23419641-8	2013	CONCLUSIONS: HD candesartan was more effective in improving plasma BNP levels and cardiac function than LD in Japanese CHF patients.	candesartan	16-27	natriuretic peptide B	Homo sapiens	67-70	
19299427-9	2009	CONCLUSION: We conclude that angiotensin-II modulation, with enalapril and candesartan, without concomitant utilization of beta-blocker lead to a decrease in BNP and an attenuation of the increase in LV end-diastolic and end-systolic volumes without a reversal of this process in the long term.	candesartan	75-86	natriuretic peptide B	Homo sapiens	158-161	
15164328-6	2004	Candesartan treatment resulted in a significant decrease of systolic and diastolic blood pressures, LV mass index (LVMI), homeostasis model assessment (HOMA) index, and plasma brain natriuretic peptide (BNP).	candesartan	0-11	natriuretic peptide B	Homo sapiens	203-206